Attached files

file filename
EX-32.1 - EX-32.1 - MERRIMACK PHARMACEUTICALS INCmack-ex321_10.htm
EX-31.2 - EX-31.2 - MERRIMACK PHARMACEUTICALS INCmack-ex312_8.htm
EX-31.1 - EX-31.1 - MERRIMACK PHARMACEUTICALS INCmack-ex311_7.htm
EX-23.1 - EX-23.1 - MERRIMACK PHARMACEUTICALS INCmack-ex231_13.htm
EX-21.1 - EX-21.1 - MERRIMACK PHARMACEUTICALS INCmack-ex211_11.htm
EX-10.23 - EX-10.23 - MERRIMACK PHARMACEUTICALS INCmack-ex1023_791.htm
EX-10.11 - EX-10.11 - MERRIMACK PHARMACEUTICALS INCmack-ex1011_790.htm
EX-4.1 - EX-4.1 - MERRIMACK PHARMACEUTICALS INCmack-ex41_792.htm
10-K - 10-K - MERRIMACK PHARMACEUTICALS INCmack-10k_20171231.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Merrimack Pharmaceuticals, Inc. (the “Company”) for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jean M. Franchi, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to her knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 12, 2018

/s/ Jean M. Franchi

 

Jean M. Franchi

 

Chief Financial Officer and Treasurer

 

(Principal Financial Officer)